Journal Article
. 2007 Oct; 110(13):4370-2.
doi: 10.1182/blood-2007-06-097014.

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30

Ezogelin Oflazoglu 1 Ivan J Stone  Kristine A Gordon  Iqbal S Grewal  Nico van Rooijen  Che-Leung Law  Hans-Peter Gerber  
  • PMID: 17909075
  •     38 citations


Increased expression of CD30 is associated with a variety of hematologic malignancies, including Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL). The anti-CD30 monoclonal antibody SGN-30 induces direct antitumor activity by promoting growth arrest and DNA fragmentation of CD30(+) tumor cells. In this study, we investigated the contributions of Fc-mediated effector cell functions to SGN-30 activity. We determined that antibody-dependent cellular phagocytosis, mediated by macrophages, to contribute significantly to antitumor activity in vitro. To delineate the identity of the host effector cells involved in mediating antitumor activity in vivo, we studied the effects of effector cell ablation in a disseminated model of HD (L540cy). Depletion of macrophages markedly reduced efficacy of SGN-30, demonstrating that macrophages contribute significantly to SGN-30 efficacy in this model. These findings may have implications for patient stratification or combination treatment strategies in clinical trials conducted with SGN-30 in HD and ALCL.

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.
E Oflazoglu, I J Stone, +6 authors, H-P Gerber.
Br J Cancer, 2008 Dec 11; 100(1). PMID: 19066610    Free PMC article.
Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB.
Simon Hallam, Monica Escorcio-Correia, +2 authors, Thorsten Hagemann.
J Pathol, 2009 Aug 08; 219(2). PMID: 19662665    Free PMC article.
New targets of therapy in T-cell lymphomas.
Jack Erter, Lapo Alinari, +6 authors, Pierluigi Porcu.
Curr Drug Targets, 2010 Mar 04; 11(4). PMID: 20196721    Free PMC article.
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
K A Blum, S-H Jung, +7 authors, Cancer and Leukemia Group B.
Ann Oncol, 2010 Apr 29; 21(11). PMID: 20423913    Free PMC article.
5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
May Kung Sutherland, Changpu Yu, +5 authors, Che-Leung Law.
MAbs, 2010 May 25; 2(4). PMID: 20495353    Free PMC article.
Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.
Diponkar Banerjee.
Adv Hematol, 2011 Feb 15; 2011. PMID: 21318045    Free PMC article.
Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.
Birgit Knoechel, Jens G Lohr.
J Autoimmun, 2013 Jul 25; 45. PMID: 23880067    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.
Stephen L Rego, Rachel S Helms, Didier Dréau.
Immunol Res, 2013 Sep 28; 58(1). PMID: 24072428
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.
Nuray Gül, Liane Babes, +7 authors, Marjolein van Egmond.
J Clin Invest, 2014 Jan 17; 124(2). PMID: 24430180    Free PMC article.
Highly Cited.
Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.
Saranya Elavazhagan, Kavin Fatehchand, +14 authors, Susheela Tridandapani.
J Immunol, 2015 Feb 11; 194(6). PMID: 25667415    Free PMC article.
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Marije B Overdijk, Sandra Verploegen, +8 authors, Paul W H I Parren.
MAbs, 2015 Mar 12; 7(2). PMID: 25760767    Free PMC article.
Highly Cited.
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Michelle Kinder, Allison R Greenplate, +2 authors, Randall J Brezski.
MAbs, 2015 May 02; 7(3). PMID: 25933349    Free PMC article.
Antibody-drug conjugates as novel anti-cancer chemotherapeutics.
Christina Peters, Stuart Brown.
Biosci Rep, 2015 Jul 17; 35(4). PMID: 26182432    Free PMC article.
Highly Cited. Review.
Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.
Kavin Fatehchand, Li Ren, +7 authors, Jonathan P Butchar.
J Biol Chem, 2015 Dec 24; 291(8). PMID: 26694610    Free PMC article.
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Robert Chen, Ajay K Gopal, +9 authors, Anas Younes.
Blood, 2016 Jul 20; 128(12). PMID: 27432875    Free PMC article.
Highly Cited.
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
Michiel Kroesen, Christian Büll, +8 authors, Gosse J Adema.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471639    Free PMC article.
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
Scott D Ramsey, Auayporn Nademanee, +14 authors, Craig H Moskowitz.
Br J Haematol, 2016 Sep 22; 175(5). PMID: 27649689    Free PMC article.
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.
David Howard, Jetzabel Garcia-Parra, +5 authors, R Steven Conlan.
Interface Focus, 2016 Dec 07; 6(6). PMID: 27920893    Free PMC article.
Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
Hong Li, Tae H Han, +2 authors, Baiteng Zhao.
J Clin Pharmacol, 2017 May 18; 57(9). PMID: 28513851    Free PMC article.
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation.
Jin Dai, Pu Fang, +8 authors, Hong Wang.
J Hematol Oncol, 2017 Jul 26; 10(1). PMID: 28738836    Free PMC article.
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Barbara Pro, Ranjana Advani, +12 authors, Andrei Shustov.
Blood, 2017 Oct 05; 130(25). PMID: 28974506    Free PMC article.
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H Staudacher, Michael P Brown.
Br J Cancer, 2017 Oct 25; 117(12). PMID: 29065110    Free PMC article.
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
Aiko Nagayama, Leif W Ellisen, Bruce Chabner, Aditya Bardia.
Target Oncol, 2017 Nov 09; 12(6). PMID: 29116596
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
Costantine Albany, Lawrence Einhorn, +3 authors, Darren R Feldman.
Oncologist, 2017 Dec 10; 23(3). PMID: 29222199    Free PMC article.
Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion.
Prakash Babu Narasimhan, Leor Akabas, +6 authors, Roshanak Tolouei Semnani.
PLoS Negl Trop Dis, 2018 Apr 19; 12(4). PMID: 29668679    Free PMC article.
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
Lekh N Dahal, Chie-Yin Huang, +10 authors, Stephen A Beers.
J Immunol, 2018 Jul 13; 201(4). PMID: 29997125    Free PMC article.
Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response.
Mahnaz Sahraei, Balkrishna Chaube, +14 authors, Yajaira Suárez.
J Clin Invest, 2019 Nov 12; 129(12). PMID: 31710308    Free PMC article.
Boosting therapeutic potency of antibodies by taming Fc domain functions.
Tae Hyun Kang, Sang Taek Jung.
Exp Mol Med, 2019 Nov 19; 51(11). PMID: 31735912    Free PMC article.
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
Jeffrey P Sharman, Jennifer J Wheler, +7 authors, Shadia I Jalal.
Invest New Drugs, 2019 Apr 18; 37(4). PMID: 30993587    Free PMC article.
An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages.
Tae Hyun Kang, Chang-Han Lee, +7 authors, George Georgiou.
Front Immunol, 2019 Apr 16; 10. PMID: 30984171    Free PMC article.
Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.
Tae Hyun Kang, Sang Taek Jung.
Biomolecules, 2020 Mar 04; 10(3). PMID: 32121592    Free PMC article.
Immunomodulatory effect of Stichopus japonicus acid mucopolysaccharide on experimental hepatocellular carcinoma in rats.
Yang Song, Shou-Jie Jin, +2 authors, Fu-Guo Yang.
Molecules, 2013 Jun 21; 18(6). PMID: 23783456    Free PMC article.
Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment.
Rena Liu, Robert J Oldham, +2 authors, Mark S Cragg.
Antibodies (Basel), 2020 Nov 21; 9(4). PMID: 33212886    Free PMC article.
Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.
Andrew T Lucas, Amber Moody, Allison N Schorzman, William C Zamboni.
Antibodies (Basel), 2021 Aug 28; 10(3). PMID: 34449544    Free PMC article.
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
Juliana T W Tong, Paul W R Harris, Margaret A Brimble, Iman Kavianinia.
Molecules, 2021 Oct 14; 26(19). PMID: 34641391    Free PMC article.
Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer.
Fuzhang Wang, Qurat-Ul-Ain Azim, +3 authors, João Manuel R S Tavares.
Saudi J Biol Sci, 2022 Jan 11; 29(1). PMID: 35002400    Free PMC article.
Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy.
Lin Tian, Anhua Lei, +4 authors, Jin Zhang.
Kidney Dis (Basel), 2022 Mar 01; 8(1). PMID: 35224005    Free PMC article.